Core Viewpoint - Anteris Technologies Global Corp. has successfully closed a public offering of 40 million shares at a price of $5.75 per share, alongside a private placement of 15.65 million shares to Medtronic, raising approximately $320 million in total gross proceeds [1][2][3]. Group 1: Offering Details - The public offering included the full exercise of underwriters' options to purchase additional shares, with shares sold at $5.75 each [1]. - The private placement involved the sale of shares to Medtronic plc at the same price of $5.75 per share [2]. - The gross proceeds from both the Offering and the Private Placement are approximately $320 million before deducting fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the Offering and Private Placement will support the next stage of growth, including the DurAVR® Transcatheter Heart Valve global pivotal trial for severe aortic stenosis patients [5]. - Funds will also be allocated to expand manufacturing capabilities and support ongoing research and development for v2vmedtech, inc., with remaining amounts designated for working capital and general corporate purposes [5]. Group 3: Financial Management - Barclays, Wells Fargo Securities, and Cantor acted as joint book-running managers for the Offering, while Wells Fargo Securities served as the sole placement agent for the private placement [4]. - The Offering was conducted under a shelf registration statement filed with the SEC, which was declared effective on January 8, 2026 [6].
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock